2-(2,3-dicarboxycyclopropyl)glycine has been researched along with MPTP Neurotoxicity Syndrome in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cano, J; Machado, A; Matarredona, ER; Santiago, M; Venero, JL | 1 |
1 other study(ies) available for 2-(2,3-dicarboxycyclopropyl)glycine and MPTP Neurotoxicity Syndrome
| Article | Year |
|---|---|
Group II metabotropic glutamate receptor activation protects striatal dopaminergic nerve terminals against MPP+-induced neurotoxicity along with brain-derived neurotrophic factor induction.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzoates; Brain-Derived Neurotrophic Factor; Corpus Striatum; Cyclopropanes; Disease Models, Animal; Dopamine; Dopamine Agents; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Glycine; Immunohistochemistry; In Situ Hybridization; Male; Microdialysis; Microglia; MPTP Poisoning; Neurons; Presynaptic Terminals; Protein Synthesis Inhibitors; Rats; Rats, Wistar; Receptors, Metabotropic Glutamate; RNA, Messenger | 2001 |